BioLineRx (BLRX) Net Income towards Common Stockholders (2011 - 2026)

BioLineRx's Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$2.2 million for Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders rose 29.84% year-over-year to -$2.2 million; the TTM figure through Dec 2025 stood at -$2.0 million (up 11.1% YoY), while the FY2025 annual figure was -$1.2 million, up 87.26% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$2.2 million, down from -$977000.0 in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $5.1 million in Q1 2025, with the low at -$23.1 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is -$0.01 (2021), against an average of -$1.7 million.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders surged 4539999900.0% in 2024, then plunged 533.92% in 2025.
• BioLineRx's Net Income towards Common Stockholders stood at -$0.01 in 2021, then changed by 0.0% to -$0.01 in 2022, then plunged by 230569999900.0% to -$23.1 million in 2023, then jumped by 86.18% to -$3.2 million in 2024, then advanced by 29.84% to -$2.2 million in 2025.
• Business Quant data shows BLRX's Net Income towards Common Stockholders at -$2.2 million in Q4 2025, -$977000.0 in Q3 2025, and -$3.9 million in Q2 2025.